A game-changer for colon cancer treatment! This study analyzed the impact of preoperative chemotherapy on nonmetastatic T4b colon cancer. Results showed that neoadjuvant chemotherapy significantly increased survival rates. Over the years, its use grew from 4% to 16%. Factors like younger age, male gender, recent diagnosis, academic centers, node-positive disease, and sigmoid colon tumors predicted higher neoadjuvant chemotherapy use. Patients who received it had better resection rates and overall survival, especially those with node-positive disease. Tailoring treatment decisions could save lives.
Journal Article by Kamel MK, Shchatsko A (…) Marar O et 6 al. in Dis Colon Rectum
Copyright © The ASCRS 2023.